Evaluating the effect of Chelidonium majus hydro-alcoholic extract alone and in combination with oxaloplatin on ovarian cancer (OVACR۳) cell line

Ovarian cancer (OC) is responsible for the greatest number of deaths related to tumors among all gynecologic cancers. Many people diagnosed with advanced stages (III and IV) of ovarian cancer experience a state of distress and urgency to find a new treatment plan. Presently, No single plan is exceptionally effective in treating recurrent ovarian cancer that is unresponsive to platinum-based therapies. Previous research has confirmed the cytotoxic effects of C. majus extract against tumors. In this research, we explored the impact of using oxaliplatin and C. majus extract, separately and together, on the development and cell death of ovarian cancer cells. We also investigated how β-catenin and TRPM۲ could potentially influence the observed outcomes. The OVACR۳ cell culture was utilized as the in vitro model. Methods: The MTT method was used to assess cell growth, while RT-qPCR was employed to measure the expression of caspase-۳, β-catenin, and ZEB۱. The level of caspase-۳ was used as an indicator of the speed of apoptosis. The combined and separate application of Oxaliplatin and C. majus extract proved to be highly successful in suppressing the growth and promoting cell death in OVACR۳ cells, showing even greater effectiveness when utilized simultaneously. Results: The RT-qPCR results demonstrated a decrease in ZEB۱ and β-catenin levels after being treated with this combination, indicating that these molecules may play a role in the observed anti-cancer effects. Furthermore, according to our results, the groups that received treatment showed a greater presence of caspase ۳ compared to the control group. Conclusion: Overall, our research validated the collaborative impact of combining oxaliplatin and C. majus extract on hindering the advancement of ovarian cancer. Additionally, we propose the potential mechanism involving the ZEB۱/β-catenin pathway as the regulator of this treatment strategy. In the future, further research could potentially confirm the appropriateness of this treatment regimen for the treatment of ovarian cancer, as well as shed light on the underlying mechanism behind its effectiveness.

کلیدواژه ها:

Ovarian cancer ، Chelidonium majus ، Oxaloplatin ، Combination therapy